Sens. Shaheen and Collins Introduce DIABETES Act to Protect Medicare Access to Insulin Pumps and Monitors
Small medical device companies and diabetes technology innovators could benefit from the bill's exclusion of continuous glucose monitors and insulin pumps from competitive bidding after 2031 and from separate reimbursement for AID system software. These changes reduce market entry barriers and encourage continued innovation in diabetes care technology.
“Including continuous glucose monitors, durable insulin pumps, and related supplies into the competitive bidding program further limits innovation and access to diabetes technologies.”
Read twice and referred to the Committee on Finance.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in Senate
The bill was officially filed and given a number. It now enters the legislative queue.
No votes have been recorded for this legislation yet.
Sens. Jeanne Shaheen and Susan Collins introduced the DIABETES Act (S. 4037) to ensure continuity of care for patients enrolling in Medicare. The bill expands coverage for self-management training and protects access to insulin pumps and CGMs by delaying competitive bidding for five years.
The DIABETES Act aims to enhance Medicare coverage for insulin pumps and continuous glucose monitors. It includes provisions to streamline the transition to Medicare for those already using these technologies and expands coverage for diabetes self-management training sessions.
Industry experts discuss how the DIABETES Act would counter CMS proposals that could limit access to new technology. The bill would allow suppliers to provide updated software for insulin systems, ensuring Medicare pays for the modern 'brains' of automated insulin delivery devices.
Document Type
Congressional Bill
Official Title
Diabetes Act
Analysis generated by AI. Always verify with official sources.